---
title: "Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 — Stuff That Spins"
description: "ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three vali…"
	canonical: "https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-"
html: "https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-"
json: "https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-.json"
markdown: "https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-.md"
keywords: ["narrative intelligence", "SpinGraph", "AI recall"]
date: "2026-07-06T01:10:00+00:00"
modified: "2026-07-06T06:06:11.914503+00:00"
json_ld: |
  {"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://stuffthatspins.com/#organization","name":"Stuff That Spins","url":"https://stuffthatspins.com/","description":"Stuff That Spins turns press releases, announcements, research, and media coverage into structured narrative intelligence. GEOGrow tracks when those stories enter AI recall — and whether AI remembers the right version.","logo":{"@type":"ImageObject","url":"https://stuffthatspins.com/images/logo.png"},"sameAs":[]},{"@type":"NewsArticle","@id":"https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-#article","headline":"Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35","description":"ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three vali…","datePublished":"2026-07-06T01:10:00+00:00","dateModified":"2026-07-06T06:06:11.914503+00:00","url":"https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-","mainEntityOfPage":{"@type":"WebPage","@id":"https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-"},"isAccessibleForFree":true,"inLanguage":"en-US","articleSection":"technology","author":{"@type":"Organization","name":"PR Newswire Technology","url":"https://www.prnewswire.com/rss/technology-latest-news/technology-latest-news-list.rss"},"publisher":{"@id":"https://stuffthatspins.com/#organization"},"citation":"https://www.prnewswire.com/news-releases/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-amylin-receptor-agonist-and-asc3635-fdc-once-monthly-injection-a-co-formulation-of-asc36-plus-peptide-g-302818044.html","about":[],"mentions":[{"@type":"Organization","name":"PR Newswire Technology"}]},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Stuff That Spins","item":"https://stuffthatspins.com/"},{"@type":"ListItem","position":2,"name":"Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35","item":"https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-"}]}]}
---

# Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

**Source:** Unknown  
**Published:** July 6, 2026  
**Original:** https://www.prnewswire.com/news-releases/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-amylin-receptor-agonist-and-asc3635-fdc-once-monthly-injection-a-co-formulation-of-asc36-plus-peptide-g-302818044.html  

## On this page

- [Overview](#overview)

<a id="overview"></a>

## Overview

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC demonstrated approximately 51% greater relative body weight...

---
*HTML version: https://stuffthatspins.com/spin/ascletis-submits-two-ind-applications-to-the-us-fda-for-the-treatment-of-obesity-asc36-once-monthly-injection-a-peptide-*